Mutations in the N-terminus of MED12 protein occur at high frequency in uterine leiomyomas and breast fibroepithelial tumours, and are frequently found in chronic lymphocytic leukaemia (CLL). MED12 mutations have been previously linked to aberrant Cyclin C-CDK8 kinase activity, but the exact oncogenic function in CLL is unknown. Here, we characterized MED12 mutations in CLL and identified recurrent mutations in 13 out of 188 CLL patients (6Á9%), which clustered in the N-terminus. MED12 mutations were associated with unmutated IGHV (P = 0Á024). Protein analysis of NOTCH1 in primary CLL samples revealed increased levels of NOTCH1 intracellular domain (NICD), the active form of NOTCH1, in the context of MED12 mutations. We found evidence that NICD is the target of Cyclin C-CDK8 kinase using a specific CDK8 inhibitor. In line with these findings, MED12 mutations were mutually exclusive to mutations in NOTCH1 in CLL, based on a meta-analysis of 1429 CLL patients (P = 0Á011). Our results suggest that MED12 mutations may contribute to CLL pathogenesis by activating NOTCH signalling.
The mediator complex subunit 12 (MED12) forms a foursubunit kinase module together with CDK8, Cyclin C and MED13 in the Mediator, a central integrator and processor of RNA polymerase II transcription (Clark et al, 2015) . This kinase module was originally reported to repress global transcription in association with the core Mediator (Elmlund et al, 2006; Knuesel et al, 2009a) . Emerging genetic and biochemical evidence supports that it can function as an oncogenic unit. This process is usually routed through the CDK8 kinase, which affects its specific targets to either promote or suppress tumourigenesis (Clark et al, 2015) . Within the kinase module, MED12 directly binds to Cyclin C and is essential to trigger Cyclin C-dependent CDK8 activation (Knuesel et al, 2009b; Turunen et al, 2014) .
MED12 mutations have been found in a variety of tumours (Makinen et al, 2011; Barbieri et al, 2012; Assie et al, 2014; Tan et al, 2015) . The majority of mutations cluster in the N-terminal part of MED12 and occur at highest frequency (59-82%) in uterine leiomyomas (Makinen et al, 2011) and breast fibroepithelial tumours (Tan et al, 2015) . In chronic lymphocytic leukaemia (CLL), a haematological disease characterized by the accumulation of mature B lymphocytes (CD5 + /CD19 + /CD23 + ) in peripheral blood, bone marrow and lymph nodes, MED12 mutations occur at a frequency of 1Á3-8Á8%, also clustering in the N-terminus (Damm et al, 2014; Guieze et al, 2015; Kampjarvi et al, 2015; Landau et al, 2015; Puente et al, 2015) . Biochemical studies revealed that these MED12 mutations lead to decreased CDK8 kinase activity by disrupting the MED12-Cyclin C binding interface, which is mapped within the N-terminal amino acids of MED12, encoded largely by exon 1 and 2 Turunen et al, 2014) . However, the exact tumourigenic role of MED12 mutations and linked aberrant CDK8 activity is unclear, as CDK8 targets diverse substrates in different cell context and affects various signalling pathways, such as NOTCH, WNT, STAT and TGFb (Fryer et al, 2004; Firestein et al, 2008; Alarcon et al, 2009; Bancerek et al, 2013; Li et al, 2014) . NOTCH signalling controls differentiation and plays a role in the tumourigenesis of multiple cancers including CLL (Rosati et al, 2009; Arruga et al, 2014) . NOTCH1 intracellular domain (NICD) serves as the signalling hub: the transmembrane NOTCH1 receptor interacts with its extracellular ligand, initiating proteolytic cleavage and release of the NICD, which subsequently translocates to the nucleus, triggering transcription (Andersson et al, 2011) . NICD has been shown to be phosphorylated at the PEST domain by the MED12-Cyclin C-CDK8 complex, leading to subsequent proteasomal degradation through the E3 ubiquitin ligase FBXW7 (Fryer et al, 2004; Li et al, 2014) . Hence, MED12 could affect NOTCH signalling as an activator of Cyclin C-CDK8. To test this hypothesis, we investigated MED12 mutations in primary cells from CLL patients and linked MED12 mutation to NOTCH activation.
Methods

Patient samples
Peripheral blood (PB) samples from consecutive patients who visited University Hospital Heidelberg between 2011 and 2015 and fulfilled standard diagnostic criteria for CLL were obtained. No patients with monoclonal B-cell lymphocytosis (MBL) were included. Patients provided written informed consent in accordance with the Declaration of Helsinki and local ethical approval (S-206/2011; S-356/2013 ). Overall, this cohort included a mix of treatment-na€ ıve (70%) and treated patients (30%) with a relatively high incidence of 17p deletions (13%) ( Table SI) . Mononuclear cells (MNCs) were isolated by centrifugation over Ficoll-Paque Premium (GE Healthcare, Freiburg, Germany) and were cryopreserved. Only patient samples with a high lymphocyte percentage were chosen for Western blot analysis (median: 91%).
Genetic characterization
Whole exome sequencing (WES) was performed for 115 CLL patients with matched blood samples. In brief, libraries were prepared on the SureSelect Automated Library Prep and Capture System (Agilent Technologies, Santa Clara, CA, USA) according to the manufacturer's protocol (version E.3). Sequencing was carried out on Illumina HiSeq 2000 machines (Illumina, San Diego, CA, USA). Reads were mapped to the human reference genome (GRCh 37.1/hg 19) using the Burrows-Wheeler Alignment tool (version 0.6.2) with default parameters and maximum insert size set to 1000 bp. BAM files were sorted with SAMtools (version 0.1.19), and duplicates were marked with Picard tools (version 1.90). The mean coverage was 1059. For the detection of single-nucleotide variants (SNVs), a genome sequencing analysis established at the German Cancer Research Centre (DKFZ) was applied, as previously described (Jones et al, 2012 (Jones et al, , 2013 . Sanger sequencing was further conducted in 73 additional patient samples by targeting exon 1 and 2. Targeted sequencing of NOTCH1 exon 34 was performed as previously described (Jethwa et al, 2013 
Cell culture, NOTCH activation and CDK8 inhibitor treatment
Primary CLL cells were cultured at 10 7 cells per ml in RPMI medium with 10% heat-inactivated human serum (SigmaAldrich, St. Louis, MO, USA). The calcium chelator EDTA was used to induce transient NOTCH activation in vitro (Rand et al, 2000) . After culturing for 12 h, CLL cells were washed with phosphate-buffered saline (PBS), re-suspended in PBS containing 5 mmol/l EDTA for 15 min and then removed by replacing the normal RPMI medium. Samples were subsequently treated with the CDK8 inhibitor (Senexin; Tocris Bioscience, Bristol, UK) or dimethyl sulfoxide (DMSO).
Western blot analysis
Whole cell lysates were extracted with radioimmunoprecipitation assay buffer (Merck/Millipore, Bedford, MA, USA) containing phosphatase/protease inhibitors (Roche, Penzberg, Germany). The lysed cell pellets were incubated on ice for 30 min. Lysates were cleared by centrifugation at 16000 g for 15 min and the protein concentration was determined using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). Proteins were mixed with 29 sodium dodecyl sulphate (SDS) sample buffer, denatured by boiling at 95°C for 10 min, resolved by 4-15% SDS-polyacrylamide gel electrophoresis and transferred to a Trans-Blot Turbo polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA, USA). The membranes were blocked with 5% skimmed milk or 5% bovine serum albumin in Tris-Buffered Saline with 
Statistical analysis
The associations between MED12 mutations and clinical characteristics were analysed using Fisher's exact test, twotailed. The mutually exclusivity between MED12 and NOTCH1 mutations were tested using Fisher's exact test, one-tailed. Statistical differences between mean values were evaluated using the Student's t-test. Overall survival (OS) was calculated from the date of sample collection to the date of last follow-up or death. Kaplan-Meier curves were compared by log-rank test. Values of P < 0Á05 were considered significant. All statistical analyses were performed using GraphPad Prism version 6 (GraghPad Software, La Jolla, CA, USA).
Results
By performing WES in 115 CLL patients with matched controls, we identified somatic mutations in exon 1 and 2 of MED12 in 7 of 115 patients (6Á1%). Sanger sequencing of exon 1 and 2 was conducted on 73 additional samples. In total, we identified MED12 mutations in 13 out of 188 CLL cases (6Á9%). Twelve of 13 mutations (92%) were missense mutations. The mutations affected highly conserved amino acids (Kampjarvi et al, 2015) in exon 1 and 2 with codons G44 (8/13) and E33 (4/13) most commonly targeted ( Fig 1A , Table I ).
We compared the frequency of MED12 exon 1 and 2 mutations across tumours characterized by the Cancer Genome Atlas (Cerami et al, 2012) and in the published literature (Makinen et al, 2011; Tan et al, 2015) . Breast fibroepithelial tumours (73%), uterine leiomyomas (70%) and CLL (6Á9%) showed the highest incidence, as previously reported (Fig 1B) .
Clinical and biological features including sex, age, Binet stage, treatment status, IGHV mutational status and cytogenetic abnormalities of patients with MED12 mutations were compared with the rest of our cohort (Table II) . Unmutated IGHV occurred significantly more frequently in patients with MED12 mutations (82% vs. 43%, P = 0Á024). We also observed a trend towards co-occurrence of MED12 mutations with trisomy 12 (42% vs. 19%, P = 0Á132).
To assess if NOTCH1 intracellular domain (NICD) levels are influenced by MED12 mutations, we analysed protein (Porter et al, 2012) . The number of samples analysed is shown in parentheses. Frequencies in breast fibroepithelial tumours and uterine leiomyomas were obtained from published literature (Makinen et al, 2011; Tan et al, 2015) . DLBCL, diffuse large B cell lymphoma; HNSCC, head and neck squamous cell carcinoma; CLL, chronic lymphocytic leukaemia.
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ª 2017 John Wiley & Sons Ltd levels of NOTCH1 in primary CLL samples (Fig 2A) . CLL with NOTCH1 PEST domain deletions showed truncated and stabilized NICD (samples denoted by an asterisk), as expected (Puente et al, 2011; Arruga et al, 2014) . NICD levels were increased in MED12 mutated cases (n = 10) compared to wild-type cases (n = 29; P < 0Á0001, Fig 2B) . In contrast, the levels of NOTCH1 transmembrane form (NTM), representing the precursor of NOTCH1 protein, did not differ significantly between MED12 wild type and mutant patients (Fig 2B) . In addition, the NICD band in Fig 2A  appeared wider in a proportion of MED12 mutant cases (9/ 10, P2-P10), suggesting that MED12 might regulate NICD post-translational modification.
As the MED12-Cyclin C-CDK8 complex has been reported to control NICD degradation (Fryer et al, 2004; Li et al, 2014) , we hypothesized that MED12 mutations could impact the stability of NICD. Therefore, we examined NICD levels after culturing CLL cells from four patients (two MED12 wild type, two mutant) in vitro for 6 h. As the NOTCH pathway is inactivated in vitro in CLL (Arruga et al, 2014) , we observed a decrease in NICD levels in all patients (Fig 2C) . Importantly, NICD in cells from MED12 mutated patients was more resistant to degradation compared to wild-type patients. These results are consistent with impaired CDK8 activity in the context of MED12 mutations as described in recent biochemical studies Turunen et al, 2014) .
To understand whether NICD could be the target of kinase CDK8 in CLL, we examined NICD levels after exposing primary CLL cells (MED12 wild-type) to the specific CDK8 inhibitor Senexin (Porter et al, 2012) . To this end, we induced NOTCH activation with EDTA after NICD was fully degraded and subsequently assessed NICD and NTM levels over time. The bands from NICD changed in size over time, implying that NICD is undergoing hyperphosphorylation-dependent degradation (Fig 2D) (Fryer et al, 2004) . We observed upregulation of NICD levels and delayed degradation after CDK8 inhibition (Fig 2E, left) . In contrast, the levels of NTM were unaffected (Fig 2E, right) . This suggests that NICD is negatively regulated by CDK8 at the post-translational level in CLL. Moreover, CDK8 inhibition did not affect NICD levels in MED12 mutated CLL cells, confirming that the CDK8 kinase activity might be impaired in the context of MED12 mutations (Fig S1) . In line with our findings, we observed MED12 mutations and NOTCH1 mutations in CLL to be mutually exclusive, based on a meta-analysis of 1429 patients (P = 0Á011; Table III) (Damm et al, 2014; Guieze et al, 2015; Landau et al, 2015; Puente et al, 2015) . Within MED12 mutant cases, no concurrent mutations in NOTCH1 were found and vice versa.
Finally, we analysed the clinical impact of MED12 mutations in the cohort of 158 patients who had follow-up information available. It is known that NOTCH1 mutations are linked to Richter transformation (Villamor et al, 2013) . However, no association for MED12 mutant patients with Richter transformation could be found (P = 0Á219) (Table II) . We did not observe a significant difference for OS between MED12 mutant and wild-type patients (P = 0Á477) (Fig S2) .
Discussion
Somatic MED12 mutations, originally found in uterine leiomyomas, have been described in many tumours, including CLL, but their role in tumourigenesis is incompletely understood. Here, we describe MED12 mutations identified in a cohort of 188 CLL patients and provide evidence that recurrent MED12 mutations may be involved in CLL pathogenesis by activating NOTCH signalling.
MED12 mutations target different protein domains depending on the tumour involved. In prostate and adrenocortical carcinoma, mutations target the central leucine/serine rich domain of the protein (Barbieri et al, 2012; Assie et al, 2014) , whereas mutations observed in leiomyomas (Makinen et al, 2011) , breast fibroepithelial tumours and CLL affect highly conserved amino acids within the N-terminus of the protein. By performing WES, we confirmed that MED12 mutations in CLL are restricted to exons 1 and 2. The mutational frequency revealed in our cohort (6Á9%) is in line with a large-scale sequencing study for MED12 in 709 CLL patients (5Á2%) (Kampjarvi et al, 2015) and a cohort of relapsed/refractory CLL (8Á8%) (Guieze et al, 2015) . We confirmed that MED12 mutations are associated with unmutated IGHV, a poor prognostic factor in CLL (Kampjarvi et al, 2015) , but did not observe poor survival in MED12 mutant patients compared to wild-type patients within a short-term follow-up.
Both functional studies and computational analyses indicated that mutations in the N-terminus of MED12 might trigger conformational changes in the binding interface of Cyclin C-CDK8 and disrupt the interaction between MED12 and Cyclin C-CDK8, leading to a diminished CDK kinase activity Turunen et al, 2014; Banaganapalli et al, 2016) . As a consequence, these MED12 mutations may increase NOTCH activation. We tested this hypothesis and showed that the activated form of NOTCH protein accumulates in primary CLL samples with MED12 mutations. A further inhibitor assay confirmed that NICD is targeted by the CDK8 kinase. NOTCH signalling is involved in sustaining CLL cell survival and apoptosis resistance (Rosati et al, 2009) , as well as modulating the migratory properties of CLL cells during the homing process (Arruga et al, 2016) . The importance of NOTCH signalling in CLL pathogenesis is also highlighted by the finding of mutations in NOTCH1 in CLL (Fabbri et al, 2011; Puente et al, 2011; Rossi et al, 2012) . About 90% of NOTCH1 mutations are PEST domain deletions, which lead to enhanced NOTCH signalling by blocking NICD degradation in CLL (Arruga et al, 2014) . The mutually exclusivity between MED12 and NOTCH1 mutations revealed in our study provides support for redundant roles in NOTCH signalling. Interestingly, mutations of FBXW7 or deletions of 6q21 (Cyclin C; CNNC), both well-established tumour suppressors promoting NICD degradation in T-cell acute lymphoblastic leukaemia (T-ALL) (Thompson et al, 2007; Li et al, 2014) , are also found frequently in CLL. This suggests a more general role of genetic aberrations in the NICD degradation machinery in CLL pathogenesis (Landau et al, 2015; Puente et al, 2015) . In addition, NOTCH1 mutations are known to be enriched in patients with trisomy 12 (Balatti et al, 2012) . Previous findings also suggested that FBXW7 mutations occur more frequently in patients with trisomy 12 (Falisi et al, 2014; Jeromin et al, 2014) . Here we found a trend of co-occurrence towards MED12 mutations and trisomy 12. These observations imply that, besides aberrations of NOTCH1, other gene mutations, such as FBXW7 and MED12, potentially leading to activated NOTCH signalling, appear to cluster in CLL patients with trisomy 12 and might contribute to CLL pathogenesis. In summary, our results suggest that recurrent MED12 mutations affect NOTCH signalling in CLL. This process is likely to be mediated by an aberrant CDK8 kinase activity, affecting its downstream target NICD. As the function of MED12 has not been fully elucidated, future studies are warranted for a deeper understanding of the role of MED12 mutations in CLL. 
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